TITLE

Oseltamivir (Tamiflu) Resistance in Seasonal Influenza A (H1N1) Viruses

AUTHOR(S)
Scully, Mary-Louise
PUB. DATE
February 2009
SOURCE
Travel Medicine Advisor;Feb2009, Vol. 19 Issue 2, p5
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
INFLUENZA ACTIVITY HAS BEEN RELATIVELY LOW THUS FAR IN THE 2008-2009 season in the United States. However, of the influenza viruses isolated and tested to date there is significant resistance among the influenza A (H1N1) viruses to the antiviral oseltamivir. As of mid-December 2008, 50 influenza A (H1N1) viruses from 12 states were tested. Ninety-eight percent were resistant to oseltamivir, but all were susceptible to zanamivir, amantadine, and rimantidine. Influenza A (H3N2) and B viruses remain susceptible to oseltamivir. In light of this information, on December 19, 2008, the CDC issued interim guidelines for antiviral treatment or prophylaxis in suspected cases of influenza. The use of influenza tests that can distinguish influenza A from influenza B is encouraged. If a patient has a positive test for influenza A and treatment is indicated, the use of zanamivir should be considered. Alternatively, the combination of oseltamivir plus rimantidine could be used. If the patient has a positive test for influenza B, oseltamivir or zanamivir (no preference) may be given. The same recommendations hold for persons who are candidates for chemoprophylaxis as well. Ideally, local or state surveillance data should be used to determine which types (A or B) and subtypes (H1N1 or H3N2) are currently circulating in a given area, but this information may not be available at the time clinical decisions need to be made. Based on preliminary information, it does not appear that oseltamivir-resistant influenza A (H1N1) viruses cause more severe symptoms compared to oseltamivir-sensitive influenza A (H1N1) viruses. In addition, since oseltamivir-resistant influenza A (H1N1) viruses are antigenically similar to the (H1N1) virus included in the 2008-2009 influenza vaccine (A/Brisbane/59/2007), ongoing influenza vaccination remains an effective strategy to prevent influenza.
ACCESSION #
36458025

 

Related Articles

  • Antiviral agents targeting the influenza virus: a review and publication analysis. EYER, L.; HRUSKA, K. // Veterinární Medicína;Mar2013, Vol. 58 Issue 3, p113 

    Influenza is a serious infectious disease, which is life-threatening especially in children, seniors and immunocompromised patients. In addition to vaccination, the development of new anti-influenza agents represents a crucial defence strategy to combat seasonal and pandemic influenza strains....

  • Seasonal and Pandemic Influenza Preparedness: Science and Countermeasures. Fauci, Anthony S. // Journal of Infectious Diseases;11/2/2006, Vol. 194, pS73 

    Influenza has not been treated with the degree of medical attention that the disease warrants. As such, there is not an adequate baseline of preparedness in the United States to deal with the potential of pandemic influenza. The National Institute of Allergy and Infectious Diseases (NIAID) has...

  • Influenza vaccines and influenza antiviral drugs in Africa: are they available and do guidelines for their use exist? Duque, Jazmin; McMorrow, Meredith L.; Cohen, Adam L. // BMC Public Health;2014, Vol. 14 Issue 1, p1 

    Background Influenza viruses cause significant morbidity and mortality in Africa, particularly among high-risk groups, but influenza vaccines and antiviral drugs may not be commonly available and used. The main aim of this study was to determine the availability and use of influenza vaccines and...

  • Antiviral drugs for seasonal influenza 2014-2015.  // JAMA: Journal of the American Medical Association;1/27/2015, Vol. 313 Issue 4, p413 

    The article focuses on the antiviral drugs used for the treatment of Influenza disease and considered as an adjunct to influenza vaccination for prophylaxis. Topics discussed include use of Oseltamivir (Tamiflu), and zanamivir (Relenza) for chemoprophylaxis and treatment of influenza, adverse...

  • Multi-Omics Studies towards Novel Modulators of Influenza A Virus-Host Interaction. Söderholm, Sandra; Yu Fu; Gaelings, Lana; Belanov, Sergey; Yetukuri, Laxman; Berlinkov, Mikhail; Cheltsov, Anton V.; Anders, Simon; Aittokallio, Tero; Nyman, Tuula A.; Matikainen, Sampsa; Kainov, Denis E. // Viruses (1999-4915);Oct2016, Vol. 8 Issue 10, p1 

    Human influenza A viruses (IAVs) cause global pandemics and epidemics. These viruses evolve rapidly, making current treatment options ineffective. To identify novel modulators of IAV-host interactions, we re-analyzed our recent transcriptomics, metabolomics, proteomics, phosphoproteomics, and...

  • Death of Dutch patient raises concerns over Tamiflu-resistant H1N1.  // Infectious Diseases in Children;Nov2008, Vol. 21 Issue 11, p46 

    The article discusses research on the death of a Dutch patient who was infected with an influenza A (H1N1) virus that proved resistant to the antiviral drug oseltamivir. It references a study published in a 2008 issue of the "New England of Journal of Medicine." The researchers also mentioned...

  • Oseltamivir-resistant influenza. Kuritzky, Louis // Primary Care Reports;May2009 Clin Briefs, p9 

    The article discusses research on the resistance of influenza A virus (FLU-A) to antiviral oseltamivir (OSTV). It references a study by N. J. Dharan and colleagues, published in an issue of "Journal of the American Medical Association." Volunteer clinicians around the U.S. found that only 12.3...

  • Impact on antiviral resistance of E119V, I222L and R292K substitutions in influenza A viruses bearing a group 2 neuraminidase (N2, N3, N6, N7 and N9). Gaymard, Alexandre; Charles-Dufant, Aymeric; Sabatier, Murielle; Cortay, Jean-Claude; Frobert, Emilie; Picard, Caroline; Casalegno, Jean-Sébastien; Rosa-Calatrava, Manuel; Ferraris, Olivier; Valette, Martine; Ottmann, Michèle; Lina, Bruno; Escuret, Vanessa // Journal of Antimicrobial Chemotherapy (JAC);Nov2016, Vol. 71 Issue 11, p3036 

    Objectives: While subtype-specific substitutions linked to neuraminidase (NA) inhibitor resistance are well described in human N1 and N2 influenza NAs, little is known about other NA subtypes. The aim of this study was to determine whether the R292K and E119V ± I222L...

  • Drug-resistant flu viruses increase by 3,000 per cent.  // GP: General Practitioner;10/7/2005, p20 

    The article cites a study conducted by U.S. researchers, which states that the level of drug resistance in influenza A viruses has increased by more than 3,000 percent over the past 10 years. The greatest increase has occurred since 2003, with 84 percent of resistant viruses emerging since the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics